株探米国株
日本語 英語
エドガーで原本を確認する
0001600620FALSE00016006202025-02-272025-02-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 27, 2025
Aurinia Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)
Canada   001-36421   98-1231763
(State or Other Jurisdiction of Incorporation)
  
(Commission File No.)
  
(IRS Employer Identification No.)

#140, 14315 – 118 Avenue
Edmonton,     Alberta    
T5L 4S6
(250) 744-2487
(Address and telephone number of registrant's principal executive offices)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class  
Trading Symbol(s)
  
Name of Each Exchange on which Registered
Common Shares, without par value   AUPH   The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐


Item 2.02
 Results of Operations and Financial Condition.

On February 27, 2025, Aurinia Pharmaceuticals Inc. (“Aurinia”) issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information in this Current Report on Form 8-K and the exhibit hereto are being furnished pursuant to this Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K and the exhibit hereto, that is furnished pursuant to this Item 2.02 shall not be incorporated by reference in any of Aurinia's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
Exhibit No. Description
99.1
104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)







SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 27, 2025

AURINIA PHARMACEUTICALS INC.
By: /s/ Joseph Miller
Name: Joseph Miller
Title:
Chief Financial Officer



EX-99.1 2 exhibit991_q42024pressrele.htm EX-99.1 Document

Exhibit 99.1
aurinalogo.jpg
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

ROCKVILLE, Maryland and EDMONTON, Alberta – February 27, 2025 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2024 and provided an update on recent corporate progress.

Fourth Quarter 2024 Financial Results
•Total Revenue: For the three months ended December 31, 2024, total revenue was $59.9 million, up 33% from $45.1 million in the same period of 2023.
–Net Product Sales: For the three months ended December 31, 2024, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $57.6 million, up 36% from $42.3 million in the same period of 2023.
–License, Collaboration and Royalty Revenue: For the three months ended December 31, 2024, license, collaboration and royalty revenue, which includes manufacturing services revenue and royalties from Aurinia’s collaboration partner, Otsuka, was $2.3 million, down 18% from $2.8 million in the same period of 2023.
•Net Income (Loss): For the three months ended December 31, 2024, net income (loss) was $1.4 million, compared to $(26.9) million in the same period of 2023.
•Cash Flow Provided by Operating Activities: For the three months ended December 31, 2024, cash flow provided by operating activities was $30.1 million, up 110% from $14.3 million in the same period of 2023.
Full Year 2024 Financial Results
•Total Revenue: For the twelve months ended December 31, 2024, total revenue was $235.1 million, up 34% from $175.5 million in 2023.
–Net Product Sales: For the twelve months ended December 31, 2024, net product sales were $216.2 million, up 36% from $158.5 million in 2023.
–License, Collaboration and Royalty Revenue: For the twelve months ended December 31, 2024, license, collaboration and royalty revenue, which includes a milestone payment, manufacturing services revenue and royalties from Otsuka, was $18.9 million, up 11% from $17.0 million in 2023.
•Net Income (Loss): For the twelve months ended December 31, 2024, net income (loss) was $5.8 million, compared to $(78.0) million in 2023.
•Cash Flow Provided by (Used in) Operating Activities: For the twelve months ended December 31, 2024, cash flow provided by (used in) operating activities was $44.4 million, compared to $(33.5) million in 2023.
Cash Position
As of December 31, 2024, Aurinia had cash, cash equivalents, restricted cash and investments of $358.5 million, compared to $350.7 million at December 31, 2023. For the year ended December 31, 2024, the Company repurchased 6.1 million of its common shares for $41.0 million.
Full Year 2025 Total Revenue and Net Product Sales Guidance
For 2025, Aurinia expects total revenue in the range of $250 million to $260 million and net product sales in the range of $240 million to $250 million.
1

Research and Development Update
In September 2024, Aurinia initiated a Phase 1 study of AUR200, its potentially best-in-class dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL). BAFF and APRIL are cytokines that stimulate B cell proliferation and activity and are upregulated in many autoimmune diseases. In preclinical studies, AUR200 potently inhibited B cell proliferation and production of IgA and IgM antibodies and exhibited pharmacokinetic and pharmacodynamic properties consistent with once-monthly dosing. Aurinia expects to report initial results from its Phase 1 study of AUR200 in the second quarter of 2025.
“We are pleased to have delivered strong LUPKYNIS sales growth in 2024,” stated Peter Greenleaf, President and Chief Executive Officer of Aurinia. “We expect 2025 to be an exciting year for Aurinia. We remain focused on increasing LUPKYNIS’s adoption among the many lupus nephritis patients who could benefit from this important treatment, while, at the same time, advancing our important pipeline product, AUR200, which has the potential to treat a wide range of autoimmune diseases.”
Webcast & Conference Call Details
A webcast and conference call will be hosted today, February 27th, at 8:30 a.m. ET. The link to the audio webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: LUPKYNIS net product sales, the timing of clinical study results and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com.
Media and Investor Inquiries:
Andrea Christopher
Corporate Communications and Investor Relations
Aurinia Pharmaceuticals Inc.
achristopher@auriniapharma.com

General Investor Inquiries
ir@auriniapharma.com
2

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands)
December 31, 2024 December 31, 2023
ASSETS
Current assets:
Cash, cash equivalents and restricted cash $ 83,433  $ 48,875 
Short-term investments 275,043  301,614 
Accounts receivable, net 36,544  24,089 
Inventory, net
 39,228  39,705 
Prepaid expenses and deposits
 11,219  9,486 
Other current assets 1,129  1,031 
Total current assets 446,596  424,800 
Finance right-of-use lease assets 92,072  108,715 
Intangible assets, net 4,355  4,977 
Operating right-of-use lease assets 4,068  4,498 
Property and equipment, net 2,731  3,354 
Long-term investments —  201 
Other noncurrent assets 823  1,517 
Total assets $ 550,645  $ 548,062 
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 5,187  $ 4,327 
Accrued expenses
 64,971  50,062 
Finance lease liabilities, current portion
 14,046  14,609 
Deferred revenue
 11,002  4,813 
Operating lease liabilities, current portion
 1,026  989 
Other current liabilities
 1,531  2,388 
Total current liabilities 97,763  77,188 
Finance lease liabilities, less current portion
 58,554  75,479 
Deferred compensation and other noncurrent liabilities 11,107  10,911 
Operating lease liabilities, less current portion 5,743  6,530 
Total liabilities 173,167  170,108 
Shareholders' equity
Common shares - no par value, unlimited shares authorized, 140,883 and 143,833 shares issued and outstanding at December 31, 2024 and 2023, respectively 1,187,696  1,200,218 
Additional paid-in capital 126,999  120,788 
Accumulated other comprehensive loss (647) (730)
Accumulated deficit (936,570) (942,322)
Total shareholders' equity 377,478  377,954 
Total liabilities and shareholders’ equity $ 550,645  $ 548,062 

3

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
Three months ended Years ended
December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023
(unaudited)
Revenue
Net product sales
 $ 57,582  $ 42,315  $ 216,186  $ 158,533 
License, collaboration and royalty revenue
 2,285  2,780  18,947  16,980 
Total revenue 59,867  45,095  235,133  175,513 
Operating expenses
Cost of revenue
 5,552  5,395  28,248  14,148 
Selling, general and administrative 37,032  50,072  172,028  195,036 
Research and development 8,107  10,228  20,785  49,641 
Restructuring
 15,351  —  23,106  — 
Other (income) expense, net
 (4,506) 9,074  (4,347) 8,379 
Total operating expenses
 61,536  74,769  239,820  267,204 
Loss from operations (1,669) (29,674) (4,687) (91,691)
Interest income
 3,988  4,568  16,970  16,997 
Interest expense
 (1,146) (1,310) (4,835) (2,775)
Net income (loss) before income taxes 1,173  (26,416) 7,448  (77,469)
Income tax (benefit) expense (256) 459  1,696  551 
Net income (loss)
 $ 1,429  $ (26,875) $ 5,752  $ (78,020)
Basic
 $ 0.01  $ (0.19) $ 0.04  $ (0.54)
Diluted
 $ 0.01  $ (0.19) $ 0.04  $ (0.54)
Shares used in computing earnings (loss) per share
Basic 142,179  142,927  143,057  143,236 
Diluted 147,675  142,927  146,194  143,236
4
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Years ended December 31,
2024 2023 2022
Cash flows from operating activities:
Net income (loss)
 $ 5,752  $ (78,020) $ (108,180)
Adjustments to reconcile consolidated net income (loss) to net cash provided by (used in) operating activities:
Share-based compensation 31,596  45,311  32,300 
Amortization and depreciation
 19,445  11,647  2,706 
Foreign exchange (gain) loss on revaluation of finance lease liability (Monoplant)
 (5,910) 5,949  — 
Net amortization of premiums and discounts on investments (12,731) (12,141) (1,572)
Non-cash write-down of inventory
 —  916  3,646 
Other, net 788  (1,515) (1,612)
Net changes in operating assets and liabilities:
Accounts receivable, net (12,455) (10,606) 1,927 
Inventory, net
 477  (15,869) (9,072)
Prepaid expenses and other current assets (1,834) 4,399  (2,404)
Other noncurrent operating assets
 31  (16) (363)
Accounts payable 860  1,240  (792)
Accrued expenses and other liabilities
 13,330  12,154  1,491 
Deferred revenue
 5,789  3,763  3,048 
Operating lease liabilities (750) (673) (652)
Net cash provided by (used in) operating activities
 44,388  (33,461) (79,529)
Cash flows from investing activities:
Proceeds from the sale and maturities of investments 585,418  529,376  464,316 
Purchases of investments (545,832) (523,500) (523,993)
Upfront lease payments
 (43) (11,864) (663)
Purchases of property, equipment and intangible assets
 (281) (718) (292)
Net cash provided by (used in) investing activities
 39,262  (6,706) (60,632)
Cash flows from financing activities:
Repurchase of common shares
 (40,239) —  — 
Principal portion of finance lease payments
 (11,989) (10,025) — 
Proceeds from issuance of common shares from exercise of stock options and vesting of RSUs 8,186  5,324  1,561 
Proceeds from issuance of common shares under ESPP
 1,084  1,850  1,912 
Taxes paid related to net settlement of exercises of stock options and vesting of RSUs (6,134) (2,279) (1,040)
Net cash (used in) provided by financing activities
 (49,092) (5,130) 2,433 
Net increase (decrease) in cash, cash equivalents and restricted cash 34,558  (45,297) (137,728)
Cash, cash equivalents and restricted cash, beginning of the period
 48,875  94,172  231,900 
Cash, cash equivalents and restricted cash, end of the period
 $ 83,433  $ 48,875  $ 94,172 
5